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Abstract
The landscape for cancer research is profoundly different today from that only one decade ago.
Basic science is moving rapidly and biotechnological revolutions in molecular targeting and
immunology have completely modified the opportunities and concepts for cancer treatment. In
contrast to the recent past where cytotoxic molecules were screened in the laboratory and then
tested in early clinical studies with toxicity as endpoint instead of the often poorly defined
mechanism for its potential anti-tumor effect, we now have entered the age of molecular
therapeutics, rationally designed to target "strategic" checkpoints that underlie the malignant
phenotype.
Translational research in early clinical trials (Phase I and II) is an integral aspect of the development
of the new generation of cancer drugs as it is necessary to implement radically different early phase
clinical trial design and to validate new biological end-points if the full potential of these new agents
is to be realized. The "proof of principle with mechanistic analysis" strategy will allow optimisation
of therapy from the beginning, and provide important feedback to pre-clinical drug developers.
Translational research is also essential in late (phase III) clinical trials in defining different patient
populations that may benefit to differing degrees from new treatments, and thus provide further
insight and refine clinical practice in a more and more patient-tailored approach. In this editorial
we will discuss the integration of Translational Research in the Organization for Research and
Treatment of Cancer (EORTC).
Translational Research in Clinical Trials must 
take priority
The landscape for cancer research is profoundly different
today from that only one decade ago. Basic science is mov-
ing rapidly and biotechnological revolutions in molecular
targeting and immunology have completely modified the
opportunities and concepts for cancer treatment. In con-
trast to the recent past where cytotoxic molecules were
screened in the laboratory and then tested in early clinical
studies with toxicity as endpoint instead of the often
poorly defined mechanism for its potential anti-tumor
effect, we now have entered the age of molecular thera-
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peutics, rationally designed to target "strategic" check-
points that underlie the malignant phenotype.
Translational research in early clinical trials (Phase I and
II) is an integral aspect of the development of the new gen-
eration of cancer drugs as it is necessary to implement rad-
ically different early phase clinical trial design and to
validate new biological end-points if the full potential of
these new agents is to be realized. The "proof of principle
with mechanistic analysis" strategy will allow optimisa-
tion of therapy from the beginning, and provide impor-
tant feedback to pre-clinical drug developers.
Translational research is also essential in late (phase III)
clinical trials in defining different patient populations
that may benefit to differing degrees from new treatments,
and thus provide further insight and refine clinical prac-
tice in a more and more patient-tailored approach.
Complexity of Translational Research
Implementation of translational research as a key compo-
nent of drug development and clinical research is complex
and involves patients in various ways. Thereby it imposes
some new ethical, legal, logistical and management con-
strains. Moreover translational research may require
highly sophisticated machines, specific imaging tech-
niques, biochemistry laboratories and imposes other
infrastructural prerequisites, some of which should be in
the direct vicinity of the clinical trial site. The usefulness
of data generated during monitoring of such clinical trials
with biologic/mechanistic endpoints is highly dependent
on the quality of the assays and the availability of suffi-
cient numbers of samples to conduct valid analyses.
Methodology Validation
Biological end-points require sufficient data on the repro-
ducibility of the technique used to define statistically valid
threshold of the biological "response". Assays used
should be validated (specific and reproducible and also
sufficiently sensitive to detect relevant "molecular signa-
ture") and appropriate controls are essentials to the inter-
pretation of any outcome in laboratory monitoring of
these trials. Early standardisation of methodology, rea-
gents used and quality control in multicentric studies are
so essential and mandate greater investment during pre-
clinical development, and is important to realize that the
tools required for translational research can take as long to
develop as the drug itself.
Tissue Banking
Translational research may impose serial (tumor) tissue
sampling during the investigational treatment. However,
a balance has to be struck between what the laboratory
researcher would prefer in terms of the size, frequency and
number of samples taken; what the clinician feels is justi-
fied and technically feasible; and what an ethics commit-
tee will accept in terms of patients' interests and well-
being, and of course what the patient can understand as
being a reasonable request and can agree to. This tissue
research needs to be supported by a specific centralized
system of management that provides a reliable and fast
toll for translational researchers and scientific exchanges
that takes into account all legal and ethical aspects.
Translational research in (multicentric) clinical trials with
will have to be conducted by multidisciplinary teams of
clinicians and basic researchers (pharmacologists, molec-
ular biologists, and biochemists), functional imaging spe-
cialists, "new-assay specialists", pathologists and
statisticians and bioinformation scientists keen to relate
biological findings to clinical outcome. These develop-
ments request that the premier laboratories are closely
knitted into comprehensive clinical development pro-
grams of new anti-cancer drugs. In order to achieve this we
need to establish a completely research minded integrated
setting of laboratories, high quality patient-centered can-
cers services and a clinical-trial-research organization that
can create, maintain and complete this circle of interac-
tions as well to provide methodology, scientific and full
logistic support.
The European Organization for Research and Treatment
of Cancer Research (EORTC) has recognized and priori-
tized the organization and implementation of transla-
tional research as a mandatory and integral part of clinical
cancer research and has developed a Translational
Research Unit and a Central as well as a Virtual Tissue
Bank system to organize, promote, coordinate and
enhance the quality of translational research in associa-
tion with its drug development program throughout the
trajectory of phase I-II-III studies. This integrated program
is described in the following paragraphs:
Role of the European Organization for Research 
and Treatment of Cancer Research (EORTC)
Need for Coordination and Centralization of Basic Science 
and Clinical Science Expertise
Translational research success depends on the creation of
a high quality research environment in which close rela-
tionship between basic scientists and clinicians are fos-
tered to avoid duplication of efforts and facilitate the
sharing of key resources in order to decrease time between
innovative agents discovery and its registration /availabil-
ity in clinical practice. At this time, there is no mechanism
to support and coordinate this centralized European
translational research effort.
Core basic scientists and oncologists experts in Europe
who are already funded to perform cancer basic labora-
tory and (early) clinical trials development should be
brought together to:Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/2
Page 3 of 5
(page number not for citation purposes)
• Establish better pre-clinical models to select rationally
designed anticancer target-based compounds, and to fur-
ther define mechanisms of anti-tumor response of these
compounds in these models;
• Evaluate the incorporation of biological endpoints into
novel early clinical trial designs that allow optimal evalu-
ation of target-based new drugs ("proof of principle with
mechanism analysis" strategy);
• Define current monitoring techniques and help to
develop the tools, probes, biological and imaging assays
suitable for in vitro assessment, in preclinical models;
• Conduct in a rapid coordinated manner highly special-
ised, complex, (early) clinical trials with rigorous stand-
ards to deliver complex, detailed data for licensing
purposes (regulatory requests);
• Assure a high quality laboratory infrastructure and
expertise with the capacity to provide biological readouts
on clinical material in a timely manner.
A Common Structural Organization for Clinical Trials with 
Translational Research Coordination
The success of the integration of high quality basic
research and clinical networks and translational research
initiatives depends greatly on the coordination of a Pan
European Clinical Trials Network.
This network should be articulated around a common
structural Organization, which should a) coordinate and
harmonize the development and submission of trial pro-
tocols to scientific and clinical independent peer review-
ers, b) innovate new trial statistical design concepts, c)
organize data management, study monitoring, and statis-
tical analysis of the data and d) ensure that European reg-
ulatory requirements as well as all the other operational
aspects to conduct appropriate translational work (from
simple items as drug supply to complex aspects such as
virtual tumor bank issues) are fulfilled.
It has been recognized by the EORTC that this type of sup-
port must be developed fully and provided by this organ-
ization. Priority for translational research in clinical
cancer research prompted the EORTC to completely
revisit its drug development pathway and operational
structures these last 2 years as well to establish a method
to fund the EORTC Groups research projects by creating a
new grant system for translational research (EORTC
Translational Research Fund).
The EORTC Drug Development Pathway with 
Translational Research
Since 1974 the EORTC has conducted clinical develop-
ment studies through its Clinical Research Division
(CRD). This has resulted in the establishment of a solid
and dedicated network of medical doctors with focussed
expertise in cancer drug development. Consistent with the
changes in cancer clinical and laboratory research, the
Laboratory Research Division (LRD) of the EORTC has re-
focused its activities in order to enhance translational
research conducted as part of EORTC clinical trials. This
EORTC LRD includes the Screening and Pharmacology
Group, the Pharmacology and Molecular Mechanisms
Group, the Receptor and Biomarker Study Group, the
Functional Imaging Group and the Pathology Group.
Through the LRD, the EORTC has access to the basic sci-
ence expertise and experience needed for target-based
drug discovery and clinical development.
The EORTC Data Center promotes and ensures an opti-
mal flow of coordination and communication by creating
translational procedures between the 2 EORTC Divisions,
including the EORTC New Drug Development Program
(NDDP), which allows for a swift continuation of scien-
tific activities from pre-clinical testing to clinical research.
In this respect, two new independent EORTC Committees
of scientific and clinical experts have been implemented
as of October 2002 to advice on the, relevance of transla-
tional and clinical research efforts, to be invested by the
organization:
The EORTC New Drug Advisory Committee (NDAC)
This NDAC reviews all proposals for new drug develop-
ment offered to the EORTC for further development. It
ensures a coherent scientific strategy with regard to drug
development and translational research. This committee
may suggest, if necessary, additional pre-clinical studies
for potential breach of pre-clinical data as well as propose
potential laboratory/facilities support for additional work
(pre-clinical models available within the EORTC LRD).
NDAC thereby serves as a scientific committee for all the
EORTC Early Clinical Trials. The NDAC comprises 10 per-
manent members.
The EORTC Translational Research Advisory Committee (TRAC)
The EORTC TRAC missions are (a) To stimulate and to
provide expert scientific and practical advice on transla-
tional research projects conducted in the context of
EORTC clinical trials. This activity includes the prioritis-
ing of projects; (b) To review and assess the EORTC Qual-
ity Assurance (QA) translational research program by
prospectively reviewing the effectiveness of the transla-
tional research studies conducted by EORTC Groups, by
supporting the EORTC Data Center in its QA assessment
of laboratories performing EORTC projects and to makeJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/2
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sure that there is a Quality Control for each assay used. All
disciplines of translational research in oncology are repre-
sented in the review panel.
The Operational Structure for Drug and Translational 
Research Development
Modernization of the mode of operation of the EORTC
Data Center and acquisition of the expertise needed to
conduct and support clinical research activities with trans-
lational research have been a necessary to proceed with
the EORTC plans for translational research. This included
the creation of a new unit and the adaptation of some
tasks of existing specialised Units, which activities have to
be coordinated during the life cycle of a clinical trial
including contemporary translational research aspects:
The Translational Research Unit
In October 2002, the EORTC implemented a Transla-
tional Research Unit (TRU) to enhance and promote
translational research projects conducted as part of
EORTC clinical trials. This Unit is primarily responsible to
generate high quality translational research trial data by:
(a) Ensuring a constant EORTC forum between the Clini-
cal and Laboratory Research Divisions of the EORTC, fos-
tering interest in translational research within Clinical
Groups and promoting clinical development of ideas/
concepts emerging from Laboratory Groups; (b) Collabo-
rating with member of the TRAC, clinicians located in
their institutions and with other staff at the Data Center
(statisticians, physicians, computer specialists, data man-
ager) to guarantee close collaboration between all actors
involved in clinical trials and translational research; (c)
Collaborating with the Protocol Writing Committee to
ensure adequacy of protocols and Case Report Forms
(CRFs) for adequate translational data capture; (d) Pro-
spectively supporting all the operational organisation
aspects of specific TR Projects; (e) Ensuring that all EORTC
translational research activities are performed according
specific working procedures, in the general framework of
EORTC policies and Standard Operating Procedures.
The EORTC Tumor Bank Unit
Since September 2000, the EORTC has set up a central Tis-
sue Bank (centralised collection and storage of glass slides
and paraffin blocks based at the EORTC Data Center,
Brussels) and a Virtual Tumor Bank with tissues being
stored at the clinical sites (with information on tissue
samples available in the central database).
This EORTC project will supply a centralised system of
management of material available from patients entered
into EORTC clinical trials and will be able to: (a) Provide
tools for efficient panel histology review (either by an
individual expert of a panel of experts) improving the
quality of the pathological diagnoses; (b) Provide a relia-
ble and fast tool to allow translational research; and (c)
Provide a web-interface to allow users to access (limited)
data of the patients stored in the clinical database.
The EORTC Tumor Bank Unit develops and implements
procedures for histology review and, in cooperation with
the Regulatory Affairs Unit, solves the legal and ethical
issues on this aspect.
Supportive Units
• The Regulatory Affairs Unit is implementing mechanisms
not only to ensure compliance of clinical trials with Euro-
pean and national requirements, but also to allow a rapid
adaptation to constantly evolving regulations and require-
ments from the competent National and European
authorities and from international standards such as
Good Clinical Practice and management of serious
adverse events. The challenges to new methodology for
clinical trials and evaluation of the outcome of new treat-
ments should also integrate all translation research infor-
mation. The Regulatory Affairs Unit is therefore involved
in all the legal aspects related to the development of trans-
lational research project, which requires an appropriate
ethical and legal framework (i.e. tissue research and
tumor bank; property of the EORTC scientific transla-
tional discoveries; legal implications of the "biological
characterization" of individual to provide appropriately
tailored therapeutic approaches). This comes at the time
where European regulatory framework will be completely
reviewed due the implementation of the new clinical trials
Directive.
• The Safety Desk and the Monitoring Unit ensure drug
developers that EORTC trials are closely controlled for
safety and accuracy. EORTC-Clinical Research Associates
will be actively involved in the day-to-day monitoring of
clinical trials, involving also the monitoring of transla-
tional research work at the hospital and the laboratory
sites.
• The Protocol Help Desk provides logistic support to the
members of the Writing Committee including the transla-
tional research study coordinator for assembling a study
protocol according to standard procedures and ensures
that the protocol is adequately developed in the shortest
possible time and according the latest methodological,
legal (e.g. SAE reporting issue) and ethical requirements
(Informed Consent requirements for clinical and transla-
tional researches studies, latest version of the declaration
of Helsinki, etc.).
The Information Technology Unit
The EORTC is one of Europe's leading players in the devel-
opment of new technologies to facilitate and speed up
cancer clinical research. Specific software is under devel-Publish with BioMed Central    and   every 
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opment following widely-accepted methodologies and
validation procedures for remote translational research
data entry (i.e. functional imaging, microarray data) to
allow adequate analysis.
The EORTC Translational Research Fund
The EORTC promotes EORTC translational researches by
establishing a method for better funding of EORTC
groups translational research projects within clinical trials
as well as through specific research projects. In that
respect, a specific Translational Research Fund (TRF) has
been created in order to fund selected high quality, inno-
vative projects with clear objectives and methods.
Each year more than 30 projects proposal are submitted.
Each project proposal is reviewed for its scientific, medical
and ethical merit by the TRAC and approved by the
EORTC Executive Committee. Intergroup TR projects
within the EORTC (Laboratory and Clinical Groups) are
always strongly encouraged in order to create an optimal
flow of interaction between the two EORTC Divisions.
This new granting system is running since 2001 and 12
projects have been already funded (5 in 2001 and 7 in
2002). These TRF grants function as "seed" money and
will hopefully result in some larger translational research
support from various sources.
EORTC Executive Committee, through the EORTC TR
Unit, monitors progress and ensures that projects are
operated within the budget. The Executive Committee
and the chairmen of NDAC/TRAC are reviewing scientific
progress twice a year.
Conclusions
Over the last five years, translational research has become
an important aspect of cancer clinical research. This has
been fostered by the development of new techniques of
investigations of the tumor biology and the emergence of
new families of potential anticancer agents. The EORTC
has adapted its funding, advice and review mechanisms to
stimulate the development of translational research
within its clinical trial network. This evolution also
encompasses some structural modifications of the EORTC
central facility to address properly the demand from
EORTC groups. The possible benefits of such initiative
will not be evaluable before another decade or so.